Newsroom
Stay up to date with Ajna BioSciences’ latest news, research advancements, and industry highlights. Explore our Newsroom for press releases, media coverage, and company updates.
Press Releases
Latest Updates from AJNA BioSciences
4. February 24, 2025
DeFloria Receives Investigational New Drug Application Clearance from FDA for Phase 2 Clinical Trial of AJA001, an Oral Cannabinoid Drug Being Developed for the Treatment of Autism Spectrum Disorder (ASD)
DeFloria plans to initiate a Phase 2 clinical trial by mid-year 2025
3. December 12, 2024
DeFloria Announces Positive Results from Phase 1 Trial of AJA001 Being Developed for the Treatment of Autism Spectrum Disorder (ASD)
Single Ascending and Multiple Ascending Dose Trial Demonstrated AJA001 to be Safe and Well-tolerated, with Formulation Optimized for ASD. Presentation at the 63rd Annual Meeting of the American College of Neuropsychopharmacology.
2. December 13, 2023
DeFloria LLC Commences Phase 1 Clinical Program for Innovative Full Spectrum Hemp Botanical Drug
Phase 1 Results to Inform Phase 2 studies in 1H24.
1. April 06, 2023
Charlotte’s Web forms Joint Venture with BAT and AJNA BioSciences to Seek FDA-Approval for Proprietary Full Spectrum Hemp Extract Botanical Drug
BAT acquires 20% stake for US$10 million, with Charlotte’s Web and AJNA each owning 40%. Renowned neurologist Dr. Orrin Devinsky, Chief Medical Advisor for AJNA, to lead the project
